Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bonetti

Showing results (11-20 of 132) with videos related to

Pageof 14
Sort By:
Anticancer Research|July 3, 2019
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point InhibitorsJacopo Giuliani, Andrea Bonetti
Anticancer Research|July 3, 2019
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/TipiracilJacopo Giuliani, Andrea Bonetti
Anticancer Research|July 3, 2019
The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and RituximabJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 11, 2019
Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?Jacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|July 4, 2018
Long-term survival in advanced pancreatic cancerJacopo Giuliani, Andrea Bonetti
Journal of Gastrointestinal Cancer|November 28, 2015
The Multidisciplinary Management of Cancer in Daily Clinical Practice: Towards a Community Hospital Comprehensive Cancer CenterJacopo Giuliani, Andrea Bonetti
Clinical Breast Cancer|March 13, 2019
Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|August 14, 2016
The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III TrialsJacopo Giuliani, Andrea Bonetti
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|February 26, 2015
Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open questionJacopo Giuliani, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 25, 2020
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancerJacopo Giuliani, Andrea Bonetti
Pageof 14

Showing results (11-20 of 132) with videos related to

Sort By:
Pageof 14
Anticancer Research|July 3, 2019
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point InhibitorsJacopo Giuliani, Andrea Bonetti
Anticancer Research|July 3, 2019
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/TipiracilJacopo Giuliani, Andrea Bonetti
Anticancer Research|July 3, 2019
The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and RituximabJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 11, 2019
Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?Jacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|July 4, 2018
Long-term survival in advanced pancreatic cancerJacopo Giuliani, Andrea Bonetti
Journal of Gastrointestinal Cancer|November 28, 2015
The Multidisciplinary Management of Cancer in Daily Clinical Practice: Towards a Community Hospital Comprehensive Cancer CenterJacopo Giuliani, Andrea Bonetti
Clinical Breast Cancer|March 13, 2019
Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|August 14, 2016
The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III TrialsJacopo Giuliani, Andrea Bonetti
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|February 26, 2015
Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open questionJacopo Giuliani, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 25, 2020
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancerJacopo Giuliani, Andrea Bonetti
Pageof 14